Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.39 |
| ▸ | MEN1 | O00255 | 5/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 8/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29663432 | 1.00 | APP (0.54) | APPKMT2AMEN1GAAKDM4E | |
| SCHEMBL29949662 | 1.00 | APP (0.54) | APPKMT2AMEN1GAAKDM4E | |
| SCHEMBL17595495 | 1.00 | APP (0.54) | APPKMT2AMEN1GAAKDM4E | |
| SCHEMBL17099827 | 1.00 | APP (0.54) | APPKMT2AMEN1GAAKDM4E | |
| SCHEMBL17099829 | 1.00 | APP (0.54) | APPKMT2AMEN1GAAKDM4E | |
| SCHEMBL17099842 | 1.00 | APP (0.54) | APPKMT2AMEN1GAAKDM4E | |
| SCHEMBL17099824 | 1.00 | APP (0.54) | APPKMT2AMEN1GAAKDM4E | |
| SCHEMBL17099867 | 1.00 | APP (0.54) | APPKMT2AMEN1GAAKDM4E | |
| SCHEMBL20307008 | 0.95 | APP (0.48) | APPKMT2AMEN1GAAKDM4E | |
| SCHEMBL21226437 | 0.95 | APP (0.52) | APPKMT2AMEN1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208916-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2024-06-27 | — | — | US | disclosed |
| EP-3119761-B1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | AMYDIS DIAGNOSTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-10005745-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170248616-A1 | IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT | Amydis, Inc. | 2017-08-31 | — | — | US | disclosed |
| US-20160326126-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208916-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, CRYAA, APBA1 | APP 1/4885KMT2A 4649/4885MEN1 2997/4885 |
| US-20160326126-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, APBA1, CRYAA | APP 1/4885KMT2A 4621/4885MEN1 2973/4885 |
| US-10005745-B2 | Amyloid targeting agents and methods of using the same | APP, APBA1, CRYAA | APP 1/4885KMT2A 4621/4885MEN1 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.